| Mgmt Confidence | Deeply disappointed by Wet AMD results; confident in DME's distinct biological rationale. |
|---|---|
| Demand Visibility | DME market includes 50% working-age adults with high treatment discontinuation rates. |
| Margin Trends | Targeting $30 million in annualized savings through workforce and cost reductions. |
| Op. Leverage | Reducing workforce by 53% to align cost structure with strategic priorities. |
| Segment Growth | Discontinuing Wet AMD; focusing all resources on DME clinical programs. |
| Capex & Debt | $118 million cash balance; evaluating levers to extend runway past Q3 2027. |
| Regulatory | DME trial protocol amended to tighten rescue criteria for non-inferiority protection. |
| Commentary | Strategic pivot to DME leveraging multi-mechanism JAK-1 and VEGF inhibition profile. |
| New Launches | DUR-VUE Phase 3 trials (Como and Capri) currently enrolling 550+ patients. |
Growth
DME market is $5B globally; $3B in US. Wet AMD program discontinued entirely.
Outlook
Top-line results for Como and Capri DME trials expected early Q4 2027.
Risks
Cash runway only extends to late Q3 2027; top-line DME data expected Q4 2027.
The company's earnings call, NASDAQ: EYPT, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
EyePoint, Inc.: key numbers
- Share price
- $0.3076Close, Nov 16
- Market cap
- $35M
- Shares outstanding
- 113.78MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from EyePoint, Inc.
All →EyePoint Q3 2026 Results: Net Loss of $95.6M, Loss Widens
EyePoint, Inc. reported a significant increase in net loss to $274.9 million for the nine months ended September 30, 2026, driven primarily by a surge in research and development expenses to $237.4 million. Total revenues declined sharply from $30.8 million to $2.0 million year-over-year, largely due to the absence of significant license and collaboration revenue seen in 2025.
- Key figure
- Net loss $95.6M
EyePoint Financial Results
EyePoint reported Q3 2026 financial results and announced a strategic prioritization of its DURAVYU Phase 3 program in Diabetic Macular Edema (DME). The company expects this prioritization to generate $30 million in annualized savings following mixed Phase 3 results in wet AMD.
“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.”
Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
EyePoint Business Update
EyePoint is implementing a strategic prioritization plan that includes a 53% workforce reduction and the early conclusion of its Phase 3 wet AMD clinical trials after the LUCIA study failed to meet its primary endpoint. The company will focus its remaining resources on the development of DURAVYU for diabetic macular edema (DME), expecting to save approximately $30 million annually while incurring $9 million in one-time restructuring charges.
EyePoint Clinical Trial Data
EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD). The trial failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the aflibercept control, although it did meet secondary endpoints related to treatment burden reduction and safety.